Skip to main content
Prescription drug costs image by TaxRebate.org.uk via Flickr

Public Pharmaceuticals As An Antidote to Big Pharma’s Market Failure

Dana Brown

Dana Brown

Director of the Next System Project more

Health & Wellbeing

Drug-resistant “superbugs” are predicted to kill more people per year than cancer by 2050. It’s a problem that’s increasingly seen as a threat to national security, with potential consequences for trade, global development and even counterterrorism.

It’s also a problem that the pharmaceutical industry is unwilling to make the investments to address, because, they say, there is no market incentive to do so.

In an article today for The American Prospect, I argue that given this “bad case of market-incentive syndrome, it is time to consider the establishment of public pharmaceutical companies as an antidote.”

The federal government has already tried all of the traditional forms of persuasion to entice pharmaceutical companies to pour more research and development money, the article says, but the strategy has failed. The crux of the issue: “the industry’s increasingly financialized business model, which puts profits over people.”

Ensuring that the public has access to next-generation antibiotics and other life-saving drugs would require severing the tie between R&D costs and sales volume, what’s referred to in the industry as “delinkage.” “The ultimate form of delinkage would be to take the development and production of medicines like these into public hands and out of the market entirely,” I write. “What’s more, Americans across the political spectrum already support the idea of a public option in pharmaceuticals.”

You can read the full article at The American Prospect.

Dana Brown

Dana Brown

Director of the Next System Project more

More related work

All health is public health

All health is public health: Busting the myths of choice and commodity

For decades, we have been sold a myth of private health. It is a myth that our health is largely a product of individual choices and personal responsibilities. It is a myth that our healthcare is a service that private corporations can provide, and for which we must pay to survive. read more
Doctor at work

Primary health care is in critical condition. Making primary care public will restore its health—and protect ours

To avoid the catastrophic effects on our health and our economy of hollowing out our primary care system, the U.S. should create a national program for universal public primary care. read more
Public pharmaceutical

Public pharmaceuticals

Public pharmaceutical enterprises are free from the constraints of profit maximization and can define their bottom line based on such values as their contributions to public health and local economic resiliency. read more